Lovastatin purification method combining auxiliary magnetic crystallization

A purification method, lovastatin technology, applied in the field of further separation and purification of lovastatin crude product through crystallization, which can solve the problem of low product purity

Active Publication Date: 2013-06-26
NEW FOUNDER HLDG DEV LLC +2
View PDF11 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The crude product is obtained after centrifugal drying, and the obtained product has low purity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lovastatin purification method combining auxiliary magnetic crystallization

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] 80g crude lovastatin was thermally dissolved in 250ml ethanol, 1.4g activated carbon was added, hot filtered, the volume was set to 280ml, divided into two parts, one part was left to stand for crystallization; Gradually cool until a large number of crystals are precipitated, stop the magnetic assistance, continue to cool to 10 ° C, suction filtration, and vacuum dry to obtain the finished product.

Embodiment 2

[0021] 80g crude lovastatin was thermally dissolved in 200ml ethanol, 1.4g activated carbon was added, hot filtered, the volume was set to 230ml, divided into two parts, one part was left to stand for crystallization; Gradually cool until a large number of crystals are precipitated, stop the magnetic assistance, continue to cool to 15 ° C, suction filtration, and vacuum dry to obtain the finished product.

Embodiment 3

[0023] 80g crude lovastatin was thermally dissolved in 300ml ethanol, 1.4g activated carbon was added, hot filtered, the volume was set to 320ml, divided into two parts, one part was left to crystallize; Gradually cool until a large number of crystals are precipitated, stop the magnetic assistance, continue to cool to 5°C, suction filtration, and vacuum dry to obtain the finished product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a lovastatin purification method combining auxiliary magnetic crystallization, which comprises the following steps: dissolving a lovastatin crude product in organic solvent, and then gradually cooling the lovastatin solution; and applying a magnetic field to the solution until crystals are precipitated, and separating and drying the crystals to obtain a lovastatin product. In the crystallization process, the ordered arrangement of lovastatin molecules is increased through auxiliary magnetic treatment, thereby increasing the quality and quantity of high-purity crystal nuclei, improving the crystallization conditions, obtaining the crystals which are high in purity and easy to separate and enhancing the product quality.

Description

technical field [0001] The invention relates to a separation and purification method of lovastatin, in particular to a method for further separation and purification of crude lovastatin extracted from Aspergillus terreus fermentation broth through crystallization. Background technique [0002] A new type of hypolipidemic drug Lovastatin (LOVASTATIN), chemical name: (S)-2-methylbutyric acid-(1S, 3S, 7S, 8S, 8aR)-1, 2, 3, 7, 8, 8a - Hexahydro-3,7-dimethyl-8-{2-[(2R,4R)-4-hydroxy-6oxo-2-tetrahydropyranyl]-ethyl}-1-naphthyl ester; The molecular formula is C 24 H 36 O 5 , the molecular weight is 404.55, and the structure is as follows: [0003] [0004] After Merck's lovastatin (Mevacor) was approved by the FDA in 1987, it immediately attracted the attention of the medical community. Lovatadine has successfully created a new stage of hypolipidemic drugs. The drug reduces the synthesis of hepatic cholesterol by inhibiting the activity of the rate-limiting enzyme hydroxyme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D309/30
Inventor 彭平郭萍张洪兰王先文
Owner NEW FOUNDER HLDG DEV LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap